Monica T. Hinds
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Monica T. Hinds has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Deirdre E. J. Anderson
Department of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA
8 shared publications - Jeremy J. Glynn
Department of Biomedical Engineering, Oregon Health & Science University , Portland, Oregon
7 shared publications - Owen J. T. McCarty
Department of Biomedical Engineering, Oregon Health & Science University, Portland, Oregon, USA
7 shared publications - Christina U. Lorentz
Department of Biomedical Engineering, Oregon Health and Science University, Portland, OR
6 shared publications - David Gailani
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
5 shared publications - Meghan E. Fallon
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine Yale School of Medicine, New Haven, CT 06511, USA; Yale Stem Cell Center, New Haven, CT 06520, USA; Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT 06520, USA
5 shared publications
Latest Publications
- Open Access
- 30 July 2026
- Published by Elsevier in JTCVS Structural and Endovascular
- Vol. 11, 100139
Transcatheter aortic valve canting creates cusp-specific thrombogenic microenvironments through altered sinus hemodynamics
- 30 July 2026
- Published by Elsevier in JTCVS Structural and Endovascular
- Vol. 11, 100139
Open AccessTranscatheter aortic valve canting creates cusp-specific thrombogenic microenvironments through altered sinus hemodynamics
- 21 June 2026
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 114 (6) , e70104
Strut Thickness and Species‐Specific Healing Are Key Considerations in Developing Zinc‐Based Biodegradable Arterial Stents
Zinc‐based biodegradable stents offer a promising solution for temporary vascular support, aiding in vessel healing while reducing long‐term complications such as thrombosis and restenosis. This study examined three zinc‐based alloys: AMZ (Zn–4.0Ag–0.6Mn–0.1Zr), ACMZ (Zn–3.5Ag–0.5Cu–0.7Mn–0.1Zr), and CMM (Zn–1.0Cu–0.6Mn–0.05 Mg), all featuring reduced wire diameters of 0.12 mm. The focus was on their microstructure, mechanical performance, thrombogenicity, and in vivo biocompatibility. The alloys were processed through cold drawing and heat treatment, resulting in ultra‐fine‐grained structures measuring less than 1 μm. Energy dispersive spectroscopy (EDS) and x‐ray diffraction (XRD) analyses confirmed the presence of strengthening intermetallic phases (AgZn 3 , CuZn 4 , and MnZn 13 ), while a uniform elemental distribution indicated solid solution strengthening. Heat treatment enhanced ductility, especially in the AMZ and ACMZ alloys, without compromising tensile strength. In vitro hemocompatibility assays showed low thrombogenicity for these alloys, with lower fibrin and FXIIa generation compared to clinical control materials. Ex vivo assessments of platelet and fibrin attachment revealed similar results to those observed with pure zinc controls. In vivo implantation of the stent materials into the abdominal aortas of mice and rats produced distinct species‐specific immune responses. Mice exhibited significant inflammation, extracellular matrix degradation, and necrosis, raising potential concerns about their biocompatibility in this model. In contrast, implants in rats resulted in only mild inflammation and limited neointimal growth, with no signs of necrosis. This suggests a more favorable and controlled healing response in rats. Morphometric analysis of Verhoeff–Van Gieson‐stained cross‐sections indicated that the 0.12 mm wires produced significantly less neointimal growth compared to previously tested 0.25 mm implants in rats, highlighting the advantages of smaller implant dimensions. Overall, these findings support the use of refined zinc‐based alloys with smaller struts for next‐generation biodegradable stents. However, the inflammatory response observed in mice emphasizes the necessity for careful selection of models in preclinical testing.
- 21 June 2026
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 114 (6) , e70104
Strut Thickness and Species‐Specific Healing Are Key Considerations in Developing Zinc‐Based Biodegradable Arterial Stents
Zinc‐based biodegradable stents offer a promising solution for temporary vascular support, aiding in vessel healing while reducing long‐term complications such as thrombosis and restenosis. This study examined three zinc‐based alloys: AMZ (Zn–4.0Ag–0.6Mn–0.1Zr), ACMZ (Zn–3.5Ag–0.5Cu–0.7Mn–0.1Zr), and CMM (Zn–1.0Cu–0.6Mn–0.05 Mg), all featuring reduced wire diameters of 0.12 mm. The focus was on their microstructure, mechanical performance, thrombogenicity, and in vivo biocompatibility. The alloys were processed through cold drawing and heat treatment, resulting in ultra‐fine‐grained structures measuring less than 1 μm. Energy dispersive spectroscopy (EDS) and x‐ray diffraction (XRD) analyses confirmed the presence of strengthening intermetallic phases (AgZn 3 , CuZn 4 , and MnZn 13 ), while a uniform elemental distribution indicated solid solution strengthening. Heat treatment enhanced ductility, especially in the AMZ and ACMZ alloys, without compromising tensile strength. In vitro hemocompatibility assays showed low thrombogenicity for these alloys, with lower fibrin and FXIIa generation compared to clinical control materials. Ex vivo assessments of platelet and fibrin attachment revealed similar results to those observed with pure zinc controls. In vivo implantation of the stent materials into the abdominal aortas of mice and rats produced distinct species‐specific immune responses. Mice exhibited significant inflammation, extracellular matrix degradation, and necrosis, raising potential concerns about their biocompatibility in this model. In contrast, implants in rats resulted in only mild inflammation and limited neointimal growth, with no signs of necrosis. This suggests a more favorable and controlled healing response in rats. Morphometric analysis of Verhoeff–Van Gieson‐stained cross‐sections indicated that the 0.12 mm wires produced significantly less neointimal growth compared to previously tested 0.25 mm implants in rats, highlighting the advantages of smaller implant dimensions. Overall, these findings support the use of refined zinc‐based alloys with smaller struts for next‐generation biodegradable stents. However, the inflammatory response observed in mice emphasizes the necessity for careful selection of models in preclinical testing.
- Open Access
Noncoaxial Transcatheter Aortic Valve Deployment Creates Cusp-Specific Thrombogenic Microenvironments Through Altered Sinus Hemodynamics
Background: Transcatheter aortic valve replacement has transformed the management of aortic stenosis; however, adverse outcomes such as leaflet thrombosis and hypoattenuating leaflet thickening remain clinically significant concerns. Flow disturbances resulting from valve canting may alter local hemodynamics and promote thrombogenic conditions. We investigated how modest transcatheter heart valve canting alters cusp-specific sinus flow and washout and promotes localized thrombogenic microenvironments associated with leaflet surface thrombus formation using particle image velocimetry, a physiologic blood loop, and tissue analysis. Methods: A patient-derived aortic root model was used to evaluate the hemodynamic and thrombogenic effects of THV canting at -10° (anti-curvature), 0° (neutral), and +10° (along-curvature). High-resolution particle image velocimetry quantified sinus flow fields and washout characteristics, and complementary whole-blood loop experiments enabled histologic assessment of leaflet-associated thrombus formation. Results: Canting redistributed systolic jet orientation and sinus recirculation in a direction-dependent manner while preserving global hemodynamic measurements. The most spatially constrained cusp showed the largest increase in stasis and the slowest washout. In the right coronary cusp, anti-curvature canting increased the fraction of sinus area with velocity magnitude 90 ) washout to 4.7 cycles versus 2.9 and 1.8 cycles, respectively. Histology localized surface-adherent platelet/fibrin thrombus to these poorly washed regions, most prominently on the right coronary cusp leaflet in anti-curvature deployments. Left and noncoronary cusp responses shifted with tilt direction, indicating redistribution rather than uniform worsening of thrombogenic conditions. Conclusions: Even modest noncoaxial deployment is sufficient to create sinus-resolved throm-bogenic microenvironments that are not captured by global gradient or effective orifice area. Deployment configuration is therefore a modifiable determinant of post-TAVR leaflet throm-bosis risk and may contribute to HALT.
Open AccessNoncoaxial Transcatheter Aortic Valve Deployment Creates Cusp-Specific Thrombogenic Microenvironments Through Altered Sinus Hemodynamics
Background: Transcatheter aortic valve replacement has transformed the management of aortic stenosis; however, adverse outcomes such as leaflet thrombosis and hypoattenuating leaflet thickening remain clinically significant concerns. Flow disturbances resulting from valve canting may alter local hemodynamics and promote thrombogenic conditions. We investigated how modest transcatheter heart valve canting alters cusp-specific sinus flow and washout and promotes localized thrombogenic microenvironments associated with leaflet surface thrombus formation using particle image velocimetry, a physiologic blood loop, and tissue analysis. Methods: A patient-derived aortic root model was used to evaluate the hemodynamic and thrombogenic effects of THV canting at -10° (anti-curvature), 0° (neutral), and +10° (along-curvature). High-resolution particle image velocimetry quantified sinus flow fields and washout characteristics, and complementary whole-blood loop experiments enabled histologic assessment of leaflet-associated thrombus formation. Results: Canting redistributed systolic jet orientation and sinus recirculation in a direction-dependent manner while preserving global hemodynamic measurements. The most spatially constrained cusp showed the largest increase in stasis and the slowest washout. In the right coronary cusp, anti-curvature canting increased the fraction of sinus area with velocity magnitude 90 ) washout to 4.7 cycles versus 2.9 and 1.8 cycles, respectively. Histology localized surface-adherent platelet/fibrin thrombus to these poorly washed regions, most prominently on the right coronary cusp leaflet in anti-curvature deployments. Left and noncoronary cusp responses shifted with tilt direction, indicating redistribution rather than uniform worsening of thrombogenic conditions. Conclusions: Even modest noncoaxial deployment is sufficient to create sinus-resolved throm-bogenic microenvironments that are not captured by global gradient or effective orifice area. Deployment configuration is therefore a modifiable determinant of post-TAVR leaflet throm-bosis risk and may contribute to HALT.
- Open Access
- 18 March 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 214, 403-418
Micropatterning transcriptionally and phenotypically reprograms endothelial cells
- 18 March 2026
- Published by Elsevier in Acta Biomaterialia
- Vol. 214, 403-418
Open AccessMicropatterning transcriptionally and phenotypically reprograms endothelial cells
- Open Access
- 1 March 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 330 (3) , H869-H873
Territory mapping the ductal-aortic junction throughout gestation is a critical and missing baseline for coarctation of the aorta
- 1 March 2026
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 330 (3) , H869-H873
Open AccessTerritory mapping the ductal-aortic junction throughout gestation is a critical and missing baseline for coarctation of the aorta
- Open Access
- 22 December 2025
- Published by Elsevier in Biomaterials
- Vol. 329, 123935
Thrombogenic characterization of alloyed and surface-modified magnesium bioresorbable metals for cardiovascular device applications
- 22 December 2025
- Published by Elsevier in Biomaterials
- Vol. 329, 123935
Open AccessThrombogenic characterization of alloyed and surface-modified magnesium bioresorbable metals for cardiovascular device applications
- 24 September 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 735, 150743
AMP dependent protein kinase regulates endothelial heparan sulfate expression in response to an inflammatory stimulus under arterial shear stress
- 24 September 2024
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 735, 150743
AMP dependent protein kinase regulates endothelial heparan sulfate expression in response to an inflammatory stimulus under arterial shear stress
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 327 (3) , H701-H714
Effects of in utero exposure to Δ-9-tetrahydrocannabinol on cardiac extracellular matrix expression and vascular transcriptome in rhesus macaques
Prenatal cannabis use is increasing and despite the public health relevance, there is limited safety data regarding its impact on offspring cardiovascular health outcomes. We used a translational, nonhuman primate model of daily edible Δ-9-tetrahydrocannabinol (THC) consumption during pregnancy to assess its effects on the fetal cardiovascular system. THC-exposed fetal vascular tissues displayed upregulation of genes involved in cellular metabolism and inflammation, suggesting that prenatal THC exposure may impact fetal vascular tissues.
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 327 (3) , H701-H714
Effects of in utero exposure to Δ-9-tetrahydrocannabinol on cardiac extracellular matrix expression and vascular transcriptome in rhesus macaques
Prenatal cannabis use is increasing and despite the public health relevance, there is limited safety data regarding its impact on offspring cardiovascular health outcomes. We used a translational, nonhuman primate model of daily edible Δ-9-tetrahydrocannabinol (THC) consumption during pregnancy to assess its effects on the fetal cardiovascular system. THC-exposed fetal vascular tissues displayed upregulation of genes involved in cellular metabolism and inflammation, suggesting that prenatal THC exposure may impact fetal vascular tissues.
- Top Cited Papers
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 290-299
Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial
BACKGROUND: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors FXI (factor XI) and FXII (factor XII) represent novel targets for device-associated thrombosis, which may mitigate bleeding risk. Our objective was to evaluate the safety and efficacy of an anti-FXI mAb (monoclonal antibody), gruticibart (AB023), in a prospective, single-arm study of patients with cancer receiving central line placement. METHODS: We enrolled ambulatory cancer patients undergoing central line placement to receive a single dose of gruticibart (2 mg/kg) administered through the venous catheter within 24 hours of placement and a follow-up surveillance ultrasound at day 14 for evaluation of catheter thrombosis. A parallel, noninterventional study was used as a comparator. RESULTS: In total, 22 subjects (n=11 per study) were enrolled. The overall incidence of catheter-associated thrombosis was 12.5% in the interventional study and 40.0% in the control study. The anti-FXI mAb, gruticibart, significantly prolonged the activated partial thromboplastin time in all subjects on day 14 compared with baseline ( P <0.001). Gruticibart was well tolerated and without infusion reactions, drug-related adverse events, or clinically relevant bleeding. Platelet flow cytometry demonstrated no difference in platelet activation following administration of gruticibart. T (thrombin)-AT (antithrombin) and activated FXI–AT complexes increased following central line placement in the control study, which was not demonstrated in our intervention study. CRP (C-reactive protein) did not significantly increase on day 14 in those who received gruticibart, but it did significantly increase in the noninterventional study. CONCLUSIONS: FXI inhibition with gruticibart was well tolerated without any significant adverse or bleeding-related events and resulted in a lower incidence of catheter-associated thrombosis on surveillance ultrasound compared with the published literature and our internal control study. These findings suggest that targeting FXI could represent a safe intervention to prevent catheter thrombosis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04465760.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 290-299
Top Cited PapersFactor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Undergoing Central Line Placement: A Phase 2 Clinical Trial
BACKGROUND: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors FXI (factor XI) and FXII (factor XII) represent novel targets for device-associated thrombosis, which may mitigate bleeding risk. Our objective was to evaluate the safety and efficacy of an anti-FXI mAb (monoclonal antibody), gruticibart (AB023), in a prospective, single-arm study of patients with cancer receiving central line placement. METHODS: We enrolled ambulatory cancer patients undergoing central line placement to receive a single dose of gruticibart (2 mg/kg) administered through the venous catheter within 24 hours of placement and a follow-up surveillance ultrasound at day 14 for evaluation of catheter thrombosis. A parallel, noninterventional study was used as a comparator. RESULTS: In total, 22 subjects (n=11 per study) were enrolled. The overall incidence of catheter-associated thrombosis was 12.5% in the interventional study and 40.0% in the control study. The anti-FXI mAb, gruticibart, significantly prolonged the activated partial thromboplastin time in all subjects on day 14 compared with baseline ( P <0.001). Gruticibart was well tolerated and without infusion reactions, drug-related adverse events, or clinically relevant bleeding. Platelet flow cytometry demonstrated no difference in platelet activation following administration of gruticibart. T (thrombin)-AT (antithrombin) and activated FXI–AT complexes increased following central line placement in the control study, which was not demonstrated in our intervention study. CRP (C-reactive protein) did not significantly increase on day 14 in those who received gruticibart, but it did significantly increase in the noninterventional study. CONCLUSIONS: FXI inhibition with gruticibart was well tolerated without any significant adverse or bleeding-related events and resulted in a lower incidence of catheter-associated thrombosis on surveillance ultrasound compared with the published literature and our internal control study. These findings suggest that targeting FXI could represent a safe intervention to prevent catheter thrombosis. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04465760.
- Open Access
- 15 December 2023
- Published by Taylor & Francis in Platelets
- Vol. 35 (1) , 2290916
Role of platelet count in a murine stasis model of deep vein thrombosis
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.
- 15 December 2023
- Published by Taylor & Francis in Platelets
- Vol. 35 (1) , 2290916
Open AccessRole of platelet count in a murine stasis model of deep vein thrombosis
Platelets are core components of thrombi but their effect on thrombus burden during deep vein thrombosis (DVT) has not been fully characterized. We examined the role of thrombopoietin-altered platelet count on thrombus burden in a murine stasis model of DVT. To modulate platelet count compared to baseline, CD1 mice were pretreated with thrombopoietin antisense oligonucleotide (THPO-ASO, 56% decrease), thrombopoietin mimetic (TPO-mimetic, 36% increase), or saline (within 1%). Thrombi and vein walls were examined on postoperative days (POD) 3 and 7. Thrombus weights on POD 3 were not different between treatment groups (p = .84). The mean thrombus weights on POD 7 were significantly increased in the TPO-mimetic cohort compared to the THPO-ASO (p = .005) and the saline (p = .012) cohorts. Histological grading at POD 3 revealed a significantly increased smooth muscle cell presence in the thrombi and CD31 positive channeling in the vein wall of the TPO-mimetic cohort compared to the saline and THPO-ASO cohorts (p < .05). No differences were observed in histology on POD 7. Thrombopoietin-induced increased platelet count increased thrombus weight on POD 7 indicating platelet count may regulate thrombus burden during early resolution of venous thrombi in this murine stasis model of DVT.